SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wan P)
 

Sökning: WFRF:(Wan P) > (2005-2009) > Does albuminuria pr...

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study

Ibsen, H. (författare)
Olsen, M. H. (författare)
Wachtell, K. (författare)
visa fler...
Borch-Johnsen, K. (författare)
Lindholm, L. H. (författare)
Mogensen, C. E. (författare)
Dahlöf, Björn, 1953 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine
Snapinn, S. M. (författare)
Wan, Y. (författare)
Lyle, P. A. (författare)
visa färre...
 (creator_code:org_t)
2006
2006
Engelska.
Ingår i: Diabetes Care. - 0149-5992. ; 29:3, s. 595-600
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • OBJECTIVE: Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events. RESEARCH DESIGN AND METHODS: In 1,063 patients with diabetes, hypertension, and left ventricular hypertrophy, UACR was measured for a mean of 4.7 years. The primary composite end point included cardiovascular death, myocardial infarction, and stroke. Cox models were run including and excluding baseline and time-varying UACR. RESULTS: Increasing baseline albuminuria related to increased risk for cardiovascular events. Reductions in UACR at years 1 and 2 were approximately 33% for losartan vs. 15% for atenolol (P < 0.001). Benefits of losartan seem to be most prominent in patients with the highest level of baseline UACR, although treatment by albuminuria interaction was only significant for total mortality. Approximately one-fifth of the superiority of losartan was explained by the greater reduction of albuminuria. Risk of the primary end point was related to the in-treatment UACR. CONCLUSIONS: Lowering of albuminuria in patients with hypertension and diabetes appears to be beneficial and should be the subject of additional study in future clinical trials.

Nyckelord

Aged
Aged
80 and over
Albuminuria/*epidemiology/urine
Antihypertensive Agents/*therapeutic use
Atenolol/*therapeutic use
Cardiovascular Diseases/*etiology/prevention & control
Creatinine/urine
Diabetes Mellitus/drug therapy/*epidemiology
Female
Humans
Hypertension/drug therapy/*epidemiology
Hypertrophy
Left Ventricular/drug therapy/*epidemiology
Losartan/*therapeutic use
Male
Middle Aged
Predictive Value of Tests
Risk
Treatment Outcome

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy